Clinical Trial

Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

Study acronym: R/R T-ALL/LBL
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase I, open-label, dose-escalation clinical trial. The primary objectives are to assess the safety of PA3-17 injection in pediatric and adolescent participants with relapsed/refractory T-lymphoblastic leukemia/lymphoma, and determine the recommended phase II dose of PA3-17 injection for this patient population. Secondary objectives include evaluating the pharmacokinetics/pharmacodynamics, preliminarily assessing clinical efficacy, and evaluating the immunogenicity of the injection.
Trial Details
NCT Number NCT07623681
Lead Sponsor PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Conditions CD7+ T-ALL/LBL
Enrollment 12 participants
Start Date 2026-06-10
Primary Completion 2026-06-30 (estimated)
Study Completion 2028-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-03